- Earlier this week, Globant announced two major collaborations: becoming Adyen’s global lead integration partner for its payments platform and teaming with PharmaMar to deploy a multi‑agent AI system that sharply accelerates cancer drug discovery workflows.
- Together, these agreements highlight how Globant is embedding its Enterprise AI and Financial Services AI Studio capabilities into mission‑critical payment and R&D infrastructures across industries.
- Next, we’ll examine how Globant’s AI‑driven cancer research platform with PharmaMar could reshape its investment narrative around enterprise AI specialization.
AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Globant Investment Narrative Recap
To own Globant, you need to believe it can turn a soft top line and pressured margins into healthier, more recurring AI platform revenue, despite sluggish 2026 revenue guidance and long sales cycles. The new Adyen and PharmaMar deals speak to that AI story but do not immediately resolve the main near term risk: subdued demand and uncertain conversion of a large pipeline into faster, more profitable growth.
The PharmaMar collaboration looks especially relevant here, because it showcases Globant’s Enterprise AI being used inside highly regulated, complex R&D environments with measurable outcomes such as over 90% retrieval accuracy and sharply shorter research cycles. For investors watching whether AI pods and platforms can move Globant away from one off projects, this kind of embedded, multi agent deployment is a concrete example of the specialization that could support higher value, stickier AI work if replicated elsewhere.
Yet against this promise, one risk investors should be aware of is how rising automation and client in housing could still pressure Globant’s pricing power and margins if...
Read the full narrative on Globant (it's free!)
Globant's narrative projects $3.0 billion revenue and $242.1 million earnings by 2028. This requires 6.1% yearly revenue growth and about a $131.8 million earnings increase from $110.3 million today.
Uncover how Globant's forecasts yield a $73.36 fair value, a 64% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already modeling Globant’s earnings rising to about US$314 million by 2028, assuming AI pods reshape margins and scale, yet the new PharmaMar and Adyen deals could either strengthen that thesis or highlight how much still depends on execution and competition in AI services.
Explore 7 other fair value estimates on Globant - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Globant research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Globant research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globant's overall financial health at a glance.
No Opportunity In Globant?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.
- Find 54 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com